Money & Markets: the latest technology to invest in – gene editing

Most people know that the dotcom boom was based on technology, but few realize that since the stock markets all started in the 1700s, the whole shooting game has been driven by technological advancements. The history of the stock market is the history of financing and technological speculation: sailing, navigation, canals, railways, radio, automobiles, electronics, computers, internet and finally internet applications like Facebook, Google and Amazon.

So the way to invest is to catch new technology at a stage where it is exciting enough to be incorporated into listed companies, but not too late to be a new entrant buying at higher and higher valuations.

Some call it investing, but it’s ultimately speculation, a less respectful way of characterizing someone who puts their money aside to support an opinion. Some will call it gambling, but the thing to remember about gambling is that there are groups of people who make huge sums of money in gambling, namely bookies and casinos, and the only difference between them and the customer. is that for “the house” the odds are skewed. in their favor. Choosing to invest in technology before it enters the mainstream is to invest with an advantage, because skill is the advantage of the stock market and detecting technology is definitely a skill.

So I wrote about the upcoming hydrogen economy and why platinum group metals are a place to invest alongside other producers and IP holders of exotic metals, but don’t never stop looking for the next big thing.

Of course, a next big thing is genetic engineering and it just hit the US stock market. Like nuclear energy, genetic engineering has been taboo since I was a child; Sci-fi monster movies are ingrained in the minds of many, with evil mutations wreaking havoc. So the good ol ‘rebranding trick seems to do the job of slipping this unstoppable technology under the radar.

It’s now called gene editing and offers hope and potential almost beyond limits. Repairing genetic diseases, the dire consequences of which afflict millions of people, is just the tip of a huge iceberg of positive possibilities, and in an incredible breakthrough, the ability to repair and modify DNA has been launched in a new era through new technology.

This technology is Crispr. I’m not a biogeneticist, but my “finance boy” understanding is that Crispr allows for an inexpensive, fast, and accurate way to slice and / or add new pieces of DNA code to existing living cells. Jennifer Doudna and Emmanuelle Charpentier received the Nobel Prize for the development of gene editing tools which led Rodolphe Barrangou’s research on yogurt to the development of bacteria in yogurt resistant to phages. (Blessed are the cheesemakers.)

By the time you read this, I’ll probably own all of the Crispr tech companies listed, which include: Crispr Therapeutic, Editas Therapeutics, Intellia Therapeutics, and Beam Therapeutics, all in the United States, but despite being a exciting cohort today, much like the hydrogen theme of the economy and for that matter cryptocurrency, this is just the start of an explosive new segment that will grow for decades and offer anxious investors to become familiar with the nuances of the field an opportunity to create wealth for much of the rest of their lives.

Right now, these companies are comparative minnows with market caps of $ 4 billion to $ 11 billion. It may sound like a lot, but when you consider that Tesla may be worth $ 700 billion and simply replace the internal combustion engine in some form of transportation, you can imagine that a technology that transforms the engine of life itself- even can command attractive valuations given enough time to enter the imaginations of traditional investors.

People always want names as tips. It is an entropic method that is as deprecated as it is popular. The key advice is that this is a new segment that is going to explode in value and that speculators / investors can embrace it as a platform for long term gains.

Biotech companies and so-called pharmas are a vital segment for investors, especially in the United States, and it is only a matter of time before the Crispr-Cas9 revolution erupts from the trade press. and does not spread to the general public. Things never go as fast as you expect, especially if you have a clear view of the future. This shortening of the field of view is an inconvenience to see what will happen next, but in the end it happens. You could have received emails in 1990 and clearly expected online systems to turn everything upside down, but you still have to wait a few more years to jump on board actions that would then go vertical.

The main idea is that it’s worth intervening early, hanging on while constantly touting the industry down to the small subgroup that will be the Colossi in 20 years time. The sooner you can find such a sector, the more potential there is. As such, now is a great time to invest, as there are segments of the crypto, hydrogen economy, and gene editing that will have a long and lucrative future for those with the courage to dig in and become experts in these technologies.